Corteva (CTVA)
NYSEMaterialsAgricultural InputsSnapshot 2026-09-04
$87.86-0.86%
Close 2026-09-04 · 1-day change
NYSEMaterialsAgricultural InputsSnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Corteva grows seed and crop protection sales steadily. Operating EBITDA is guided near $4.1 billion in 2026. The planned seed business spin-off is on track for late 2026. New product partnerships boost crop protection revenue.
Pricing pressures and cost challenges could hurt margins. The spin-off may face delays or operational disruptions. Revenue growth is modest, near 4%, which may disappoint if costs rise.
The stock trades about 25% above our fair value near $69, reflecting roughly 4% revenue growth. Our fair value is 24% below the Street median, which is more optimistic. We see risk in margin and execution.
Breaks if: Crop Protection net sales fall below $1.78 billion
Breaks if: Operating EBITDA falls below $4.0 billion
Spin-off delayed beyond 2026-Q4
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on the Materials sector. The current thesis state is weakened due to recent financial performance that has dropped significantly within its industry.
The market appears to be pricing in a low level of fragility, but there is a stretched valuation compared to peers. This suggests that investors may have moderate expectations for recovery, but the recent decline in company quality raises concerns.
Fundamentals may continue to be challenged in the near term, given the fragile earnings quality and recent weak performance. However, management is on track with key priorities, such as completing the planned separation and driving growth in the Seed segment.
The thesis hinges on several factors, including the company's ability to maintain or improve financial guidance and the overall performance of the Materials sector. Additionally, any reversal in guidance could significantly impact credibility and market perception.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change indicates a weakened reason to own the stock. The latest earnings beat and strong demand for high-tech seeds support growth in the Seed segment. However, the overall standing has deteriorated significantly.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Execute the spin-off of the seed business into an independent publicly traded company by the fourth quarter of 2026, including leadership appointments and regulatory filings.
Stated as a priority in 4 of last 4 quarters. Management consistently emphasized completing the planned separation by the second half of 2026, with milestones such as naming the New Corteva CEO and filing Form 10 achieved by 2026-Q2. The trajectory is delivering as planned with no delays reported.
“Corteva remains on track to complete the planned separation in the second half of 2026.”
“On track for 4Q 2026 separation; named New Corteva CEO; filed initial Form 10.”
“On track to complete the planned separation in the second half of 2026.”
“Planned separation in the second half of 2026 is driven by belief it will create long-term value.”
Breaks if: Seed net sales fall below $4.54 billion
Over the next 1 to 3 years, CTVA's trajectory will depend on its execution of strategic priorities and external market conditions. Not investment advice.